Skip to content

US · MEDS · MEDICAL - DISTRIBUTION

DataMEDS AI, Inc. (MEDS) intrinsic value and stock valuation

$1.34as of 2026-11-21 · Mkt cap 7.35M

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

DataMEDS AI, Inc. DCF and intrinsic value

InvestorsCraft values MEDS with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from MEDS’s statements →

DataMEDS AI, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Medical - Distribution Tampa, FL 33607 datamedsai.com

How the business is doing

Fiscal 2022–2025, USD

Revenue
$23.3M
20222025
Net income
-$-101.27M
20222025
Free cash flow
-$-10.86M
20222025
Total equity
-$-12.45M
20232025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2022–2025, USD
2025202420232022
Revenue$23.3M$18.1M$0.00$32.8M
Operating income-$-81.19M-$-6.15M-$-2.88M-$-3.42M
Net income-$-101.27M-$-6.86M-$-2.9M-$-2.74M
EPSd-$-71.32M-$-6.6M-$-3.26M-$-2.88M
Operating cash flow-$-10.86M-$-1.22M-$-350K$0.00
Capital expenditure$0.00-$-380K$0.00$0.00
Free cash flow-$-10.86M-$-1.6M-$-350K$0.00
Total assets$30.5M$57.3M$340K—
Total debt$24.8M$25.1M$700K—
Net debt$24.7M$24.1M$700K—
Total equity-$-12.45M$6.73M-$-2.9M—
Cash and short-term investments$40K$1.03M$0.00—
Income statement
2025202420232022
Revenue$23.3M$18.1M$0.00$32.8M
Cost of revenue$33M$16.4M$0.00$27M
Gross profit-$-9.64M$1.77M$0.00$5.75M
Research and development expenses$0.00$0.00$0.00$0.00
Selling, general and administrative expenses$71.6M$6.8M$2.88M$7.08M
Other expenses$0.00$1.11M-$0.00$2.09M
Operating expenses$71.6M$7.91M$2.88M$9.17M
Cost and expenses$104.5M$24.3M$2.88M$36.2M
Interest income$0.00$0.00$0.00$0.00
Interest expense$4.58M$830K$20K$290K
Depreciation and amortization$3.21M$1.11M$0.00$2.09M
Ebitda-$-93.48M-$-4.91M-$-2.88M-$-370K
Operating income-$-81.19M-$-6.15M-$-2.88M-$-3.42M
Total other income/expenses, net-$-20.08M-$-710K-$-20K$680K
Income before tax-$-101.27M-$-6.86M-$-2.9M-$-2.74M
Income tax expense$0.00$0.00$0.00$0.00
Net income-$-101.27M-$-6.86M-$-2.9M-$-2.74M
Weighted average shares outstanding$1.42M$1.04M$890K$950K
Weighted average diluted shares outstanding$1.42M$1.04M$890K$950K
Balance sheet
202520242023
Cash and short-term investments$40K$1.03M$0.00
Net receivables$1.14M$3.75M$340K
Inventory$1.64M$9.52M$0.00
Total current assets$2.82M$15.2M$340K
Property, plant and equipment, net$1.2M$1.92M$0.00
Goodwill and intangible assets$24.5M$38.6M$0.00
Long-term investments$0.00$20K$0.00
Total non-current assets$27.6M$42.2M$0.00
Total assets$30.5M$57.3M$340K
Accounts payable$11.7M$6.33M$1.04M
Short-term debt$11.6M$12.6M$350K
Deferred revenue$490K$250K$0.00
Total current liabilities$29.8M$38.1M$2.89M
Long-term debt$13.1M$12.6M$350K
Deferred revenue, non-current$0.00$0.00$0.00
Total non-current liabilities$13.1M$12.6M$350K
Capital lease obligations$570K$1.62M$0.00
Total liabilities$42.9M$50.6M$3.24M
Common stock$10K$10K$0.00
Retained earnings-$-111.03M-$-9.76M-$-2.9M
Accumulated other comprehensive income (loss)$0.00$0.00$0.00
Total equity-$-12.45M$6.73M-$-2.9M
Total investments$0.00$20K$0.00
Total debt$24.8M$25.1M$700K
Net debt$24.7M$24.1M$700K
Cash flow statement
2025202420232022
Net income-$-101.27M-$-6.86M-$-2.9M-$-10K
Depreciation and amortization$190K$1.11M$0.00$0.00
Stock-based compensation$54.8M$1.08M$0.00$0.00
Change in working capital$8.48M$3.34M$2.55M$10K
Accounts receivable$800K-$-40K-$-270K$0.00
Inventory$1.89M-$-70K$0.00$0.00
Accounts payable$2.2M-$-880K$1.03M$10K
Net cash provided by operating activities-$-10.86M-$-1.22M-$-350K$0.00
Investments in property, plant and equipment-$-880K-$-380K$0.00$0.00
Acquisitions, net$0.00$930K$0.00$0.00
Net cash used for investing activities-$-880K$470K$0.00$0.00
Common stock issued$12.9M$10K$0.00$0.00
Common stock repurchased$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00
Net cash used for financing activities$10.8M$1.78M$350K$0.00
Net change in cash-$-990K$1.03M$0.00$0.00
Cash at end of period$40K$1.03M$0.00$0.00
Operating cash flow-$-10.86M-$-1.22M-$-350K$0.00
Capital expenditure$0.00-$-380K$0.00$0.00
Free cash flow-$-10.86M-$-1.6M-$-350K$0.00
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About DataMEDS AI, Inc.

        DataMEDS AI is a Health IT company focused on the vertical integration of technology, pharmacy, pharmaceutical-adjacent, and telemedicine business units. The company incorporates its artificial intelligence platform EinsteinRx™ and blockchain-enabled smart contacts platform PharmacyChain™ to optimize the prescription medicines reimbursement and dispensing journey.

        CEO
        Prashant Patel
        Employees
        31
        Beta
        -1.52

        Explore

        Frequently asked questions

        What is the intrinsic value of DataMEDS AI, Inc. (MEDS)?

        InvestorsCraft does not currently publish an intrinsic value for MEDS. How the IC value is calculated.

        Is MEDS undervalued?

        InvestorsCraft does not publish an undervaluation signal for MEDS at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.